Compare CLWT & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | BIAF |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 9.2M |
| IPO Year | 1996 | 2022 |
| Metric | CLWT | BIAF |
|---|---|---|
| Price | $1.45 | $3.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.9M |
| Earning Date | 04-30-2026 | 11-13-2026 |
| Dividend Yield | ★ 9.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,900,000.00 |
| Revenue This Year | N/A | $18.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | ★ 14.49 |
| 52 Week Low | $0.99 | $0.37 |
| 52 Week High | $2.68 | $21.52 |
| Indicator | CLWT | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 37.47 |
| Support Level | $1.46 | $3.31 |
| Resistance Level | $1.74 | $5.93 |
| Average True Range (ATR) | 0.15 | 0.81 |
| MACD | 0.03 | -0.46 |
| Stochastic Oscillator | 23.85 | 8.78 |
Euro Tech Holdings Co Ltd is mainly a distributor of a wide range of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies, and power generation equipment, including recorders and power quality analyzers. The Company acts as an exclusive or non-exclusive distributor for manufacturers of such equipment to commercial customers and governmental agencies in Hong Kong and mainland China, as well as commercial customers in Macau. It has two operating segments: Trading and manufacturing, which generate maximum revenue and act as a distributor of water treatment equipment, laboratory instruments, analyzers, test kits, related supplies, and power generation equipment; and the Engineering segment. The Company generates maximum revenue from the PRC.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.